BURLINGTON, Mass., Oct. 24, 2017 /PRNewswire/ -- Biopharmaceutical commercial teams are benefitting from an exciting array of data-driven insights, revealing precise prescribing patterns and pinpointing commercial opportunities across the clinical journey — thanks to some of the most sophisticated analysis yet of real world data (RWD).
Treatment Algorithms: Claims Data Analysis is a groundbreaking product from Decision Resources Group (DRG) that harnesses the power of longitudinal patient-level U.S. claims data to build a true, quantitative picture of the clinical pathway within a single disease market. It explores how patients advance through different lines of treatment following diagnosis, including which drugs they start on, which ones they progress to, and what proportion of patients funnel into various types of therapies.
The report offers six key areas of analysis:
- Prescribing behavior: Longitudinal patient-level claims data reveals physicians' actual prescribing behaviors, instead of relying on conventional primary market research to determine treatment patterns.
- New patient segmentation: Calculates brand share among newly diagnosed patients and quantifies the opportunity to position products in earlier lines of treatment.
- Recently treated patient segmentation: Captures data from patients treated in the last three months of the study period to define the source of business for each brand in the market.
- Detailed switching analysis: Identifies which competitors are a threat and which represent an opportunity to steal market share.
- Persistency and compliance: Plots drug usage trends for each therapy, aiding more accurate short-term forecast modeling.
- Patient flow diagrams: Creates detailed patient flow analyses, following newly diagnosed patients through three lines of therapy, which can be used to update existing models.
For most biopharmaceutical companies, working with RWD is a costly and time-consuming exercise, and producing meaningful results requires a great deal of therapeutic and analytical expertise. Treatment Algorithms: Claims Data Analysis removes those barriers, offering rich, clean data and deep analysis, that comes wrapped in actionable insights.
Here are a few examples of actual insights generated by current disease reports:
- Type 2 Diabetes: In first-line therapy for newly diagnosed patients, injectables account for a surprisingly large percentage of patient share. Usually reserved for third or fourth lines of therapy, 6.5% of newly diagnosed patients received a long-acting insulin, 2.4% received a GLP-1 agonist, and 3.1% received a rapid-acting insulin.
- Chronic Heart Failure: The majority of patients are persistent, with most drugs recording a persistency rate of more than 60% during the study period. Furthermore, patients are highly compliant with their medication, filling their prescriptions as scheduled at least 80% of the time.
- Rheumatoid Arthritis: Nearly half of newly diagnosed patients progressed to DMARD therapy within three years of diagnosis. First-line treatment consists of monotherapy for the vast majority of newly diagnosed RA patients, whereas combination therapy sharply increases in second- and third-line therapy to reach nearly 40% or more of patients.
- Human Immunodeficiency Virus (HIV): The three brands Descovy, Odefsey, and Genvoya (containing tenofovir alafenamide) experienced the largest growth in patient share among recently treated patients, largely fueled by patients switching regimens. Between 21.1% and 43.4% of the patient share of these three brands among recently treated patients is a result of switching.
- Alzheimer's Disease: Less than half of newly diagnosed patients receive drug treatment within the first year of diagnosis. When patients do receive therapy, it is typically within two months of diagnosis. Various factors such as denial of diagnosis, mild symptoms, or concerns about adding chronic daily medication/tolerability could delay treatment initiation, counter to the recognized importance of early intervention.
"By applying RWD and therapeutic expertise to the clinical journey, Treatment Algorithms: Claims Data Analysis gives commercial teams the information they need to make important decisions," says Mladen Tomich, Therapy Leader, Biopharma Insights, DRG. "It's the longitudinal component that makes the product truly unique, and it's the deep analytical insight that makes it invaluable."
About Treatment Algorithms: Claims Data Analysis
Treatment Algorithms: Claims Data Analysis uses a large sample of U.S. claims data that has been cleaned, analyzed, tested and checked by a team of data/analytics and therapeutic experts. The comprehensive report includes key data findings and insights, with the granular underlying data provided in an interactive supplement. 2017 coverage comprises a growing portfolio of individual reports for 31 indications, with more planned for 2018. The product is designed to accommodate on-demand requests for almost any disease for which the claims data exists.
Treatment Algorithms: Claims Data Analysis is a companion product to Current Treatment: Physician Insights, which uses primary market research to gather direct physician insights on prescribing behaviors and treatment patterns within a disease category; and to Patient Profiler, which integrates claims and EHR data to provide disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use.
For information on Treatment Algorithms: Claims Data Analysis, please visit our website.
About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.
Decision Resources Group
SOURCE Decision Resources Group